This analysis reveals plants' potential in producing monoclonal antibodies and recombinant proteins, emphasizing scalability and economic benefits.
In recent decades, plants have been widely used as a biotechnological platform for the production of recombinant protein. Plants as a bioreactor are capable of producing monoclonal antibodies, oral vaccines, and therapeutic proteins. Plants antibodies from has same advantages over antibodies obtained from bacterial culture or mammalian cell culture. Obtaining recombinant proteins is much more economical and profitable in plant culture. Plants as a bioreactor have a high level of scalability and biological safety for animals and humans.
No takes yet. Share an insight, caveat, or question.
EGORYCHEV et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: